Status:

WITHDRAWN

Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol

Lead Sponsor:

University of Dundee

Conditions:

Asthma

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The objective of this study is to compare the peak dose relative bronchoprotection offered by levosalbutamol and racemic salbutamol in mild to moderate asthmatics preselected into two groups on the ba...

Eligibility Criteria

Inclusion

  • Mild to moderate stable asthmatics on ≤ 2000μg BDP or equivalent
  • Methacholine responsive PC20\< 4 mg/ml
  • \>1dd change in methacholine PC20 after the administration of racemic Salbutamol.
  • Male or female 18-65
  • Informed Consent
  • Ability to comply with the requirements of the protocol

Exclusion

  • Severe asthmatics as defined by an FEV1≤ 60% or PEF variability \> 30% or with continual daytime or nocturnal symptoms.
  • The use of oral corticosteroids within the last 3 months.
  • Recent respiratory tract infection (2 months).
  • Significant concomitant respiratory disease such as COPD, CF, ABPA, bronchiectasis and active pulmonary tuberculosis.
  • Any other clinically significant medical condition such as unstable angina, acute myocardial infarction in the preceding 3 months, recent TIA/ CVA,that may endanger the health or safety of the participant, or jeopardise the protocol.
  • Any significant abnormal laboratory result as deemed by the investigators
  • Pregnancy, planned pregnancy or lactation
  • Known or suspected contra-indication to any of the IMP's
  • Concomitant use of medicines (prescribed, over the counter or herbal) that may interfere with the trial.

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2010

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00830882

Start Date

January 1 2009

End Date

January 1 2010

Last Update

June 12 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Asthma and Allergy Research Group

Dundee, Angus, United Kingdom, DD1 9SY

Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol | DecenTrialz